Merck & Co. is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical giant.

Merck and Japan-based Eisai said on Friday a combination of their therapies failed to extend the lives of patients with a ...

Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

Based on a survey of cardiologist and pulmonologists treating patients for pulmonary arterial hypertension (PAH), analysts at ...

Merck and Co. expects to launch an easier-to-administer version of its blockbuster cancer treatment Keytruda before the end ...

The unsuccessful Phase III results are the latest to suggest that the blockbuster cancer drug is finally bumping up against ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

“Our pipeline is broadening. I think that is an important part of thinking about the future of Merck beyond 2028,” said Dr.

Merck CEO Rob Davis told CNBC's Jim Cramer that there's more to the pharmaceutical giant than its lucrative cancer drug, Keytruda, and he described other ventures in its portfolio. "Keytruda has ...

Yahoo Finance senior health reporter Anjalee Khemlani explains the process and the range of other drugs on this new list from pharmaceutical giants Pfizer (PFE), AstraZeneca (AZN), Merck (MRK ...

Discover why Merck presents a compelling long-term investment opportunity with its discounted valuation, robust pipeline, and ...